Interleukin-1β converting enzyme : synthesis of hydroxyethyl dipeptide surrogate-containing compounds as potential ICE inhibitors

A series of compounds containing a hydroxyethyl-based dipeptide surrogate have been prepared as probes to evaluate the possibility of ICE being an aspartic protease. The aldehyde t-BocAsp(beta-t-butyl)H reacted with the organochromium species derived from phenethyl bromide and CrCl2 to give the expected addition product. Lactonization, reprotection of the amine and oxidation with RuCl3 gave the two protected dipeptide surrogates 7a and 7b. These were incorporated into tetra-, penta- and hexapeptide-like molecules and evaluated as inhibitors of the enzyme. The failure of these compounds to inhibit ICE indicated that this enzyme was very unlikely to be an aspartic protease.

[1]  R. Robinson,et al.  Synthesis of a peptidyl difluoro ketone bearing the aspartic acid side chain: an inhibitor of interleukin-1.beta. converting enzyme , 1992 .

[2]  K. Chapman.  Synthesis of a potent, reversible inhibitor of interleukin-1β converting enzyme , 1992 .

[3]  K. O. Elliston,et al.  A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes , 1992, Nature.

[4]  C. March,et al.  Molecular cloning of the interleukin-1 beta converting enzyme. , 1992, Science.

[5]  J. Weidner,et al.  IL-1-converting enzyme requires aspartic acid residues for processing of the IL-1 beta precursor at two distinct sites and does not cleave 31-kDa IL-1 alpha. , 1991, Journal of immunology.

[6]  C. Dinarello.  Interleukin-1 and interleukin-1 antagonism. , 1991, Blood.

[7]  R. Black,et al.  Substrate specificity of the protease that processes human interleukin-1 beta. , 1990, The Journal of biological chemistry.

[8]  J. Park,et al.  Glycosyl .alpha.-amino acids via stereocontrolled buildup of a penaldic acid equivalent. A novel synthetic approach to the nucleosidic component of the polyoxins and related substances , 1990 .

[9]  D. Rich,et al.  Synthesis of D-lysine8-cyclosporine A. Further characterization of BOP-Cl in the 2-7 hexapeptide fragment synthesis , 1990 .

[10]  K. Takai,et al.  Preparation of alkylchromium reagents by reduction of alkyl halides with chromium(II) chloride under cobalt catalysis , 1989 .

[11]  P. Cameron,et al.  Identification of a monocyte specific pre-interleukin 1 beta convertase activity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Rich,et al.  Inhibition of aminopeptidases by peptides containing ketomethylene and hydroxyethylene amide bond replacements. , 1989, Journal of medicinal chemistry.

[13]  R. Black,et al.  Activation of interleukin‐ 1β by a co‐induced protease , 1989 .

[14]  C. Debouck,et al.  Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[15]  William R. Taylor,et al.  A structural model for the retroviral proteases , 1987, Nature.

[16]  J. Plattner,et al.  A synthesis of protected aminoalkyl epoxides from .alpha.-amino acids , 1987 .

[17]  W. Christ,et al.  Catalytic effect of nickel(II) chloride and palladium(II) acetate on chromium(II)-mediated coupling reaction of iodo olefins with aldehydes , 1986 .

[18]  R. Baker,et al.  The synthesis of a precursor to pentalenene using a palladium(O) catalysed (3 + 2) cycloaddition , 1985 .

[19]  R. Schwyzer,et al.  Hormon-Rezeptor-Wechselwirkungen. Synthese von α-Melanotropin und von informationstragenden Teilsequenzen unter Verwendung alkalilabiler Schutzgruppen , 1975 .

[20]  B. Henderson,et al.  Therapeutic potential of cytokine manipulation. , 1992, Trends in pharmacological sciences.

[21]  D. Norbeck,et al.  Chapter 15. HIV Protease Inhibitors , 1991 .